{"id":283,"date":"2026-08-16T00:00:00","date_gmt":"2026-08-16T00:00:00","guid":{"rendered":"https:\/\/southshorenow.ca\/?p=283"},"modified":"2026-08-16T00:00:00","modified_gmt":"2026-08-16T00:00:00","slug":"retatrutide-what-the-new-triple-agonist-drug-means-for-weight-loss-and-diabetes-treatment","status":"publish","type":"post","link":"https:\/\/southshorenow.ca\/2026\/08\/16\/retatrutide-what-the-new-triple-agonist-drug-means-for-weight-loss-and-diabetes-treatment\/","title":{"rendered":"Retatrutide: What the New Triple Agonist Drug Means for Weight Loss and Diabetes Treatment"},"content":{"rendered":"

Retatrutide (LY3437943) is a first-in-class triple agonist medication that simultaneously activates three hormone receptors to treat obesity and type 2 diabetes, showing weight loss results of up to 24% in clinical trials. Unlike earlier treatments that target one or two pathways, this experimental drug works on GIP, GLP-1, and glucagon receptors at once, making it potentially more effective than current options including the GLP-3 RT peptide<\/a> and other dual-combination therapies.<\/p>\n

For Nova Scotians managing weight or metabolic health, understanding retatrutide matters now because the medication is advancing through late-stage clinical development and could reach Canadian markets within the next few years. Early research suggests it delivers superior weight reduction compared to existing GLP-1 medications, with some participants losing over 50 pounds during trial periods.<\/p>\n

The triple-action mechanism addresses appetite regulation, insulin sensitivity, and energy metabolism simultaneously. This comprehensive approach explains why trial participants experienced not just weight loss but also improvements in blood sugar control, liver fat reduction, and cardiovascular markers. While retatrutide isn’t yet approved by Health Canada, the promising data has captured attention from healthcare providers and patients alike who are watching for new therapeutic options.<\/p>\n

This article breaks down what retatrutide is, how the science works in practical terms, what the clinical evidence shows about safety and effectiveness, and what local residents should know about future availability through Nova Scotia’s healthcare system.<\/p>\n

Key Takeaway:<\/strong> Retatrutide activates three hormone receptors (GLP-1, GIP, and glucagon) instead of one or two, combining appetite control, improved blood sugar regulation, and enhanced fat burning in a single medication. This multi-pronged approach explains the significant weight loss results seen in clinical trials.<\/div>\n

How Retatrutide Works: The Triple Agonist Mechanism<\/h2>\n
\n \"Clinician
A clinician prepares an injection device in a calm clinic setting, reflecting how treatments are typically administered with medical guidance.<\/figcaption><\/figure>\n

Retatrutide targets three different hormone receptors in your body at once, which is why researchers call it a triple agonist. To understand what makes this unusual, think of your metabolism as a complex system with multiple control panels. Most weight-loss drugs flip just one switch, while Retatrutide activates three simultaneously.<\/p>\n

The first receptor is GLP-1, which you may have heard about if you’re familiar with drugs like Ozempic or Wegovy. This hormone helps control blood sugar by triggering insulin release when you eat and slows down how quickly food leaves your stomach. The result is that you feel full longer and experience fewer blood sugar spikes after meals.<\/p>\n

The second target is GIP, another gut hormone that works alongside GLP-1 but through a different pathway. GIP receptors help regulate how your body stores fat and processes glucose. When activated, they can improve insulin sensitivity and may help shift where your body stores fat, potentially reducing the more harmful visceral fat around your organs.<\/p>\n

The third receptor is glucagon, which plays a different role entirely. While GLP-1 and GIP primarily help with blood sugar and appetite, glucagon receptors boost your metabolism by increasing energy expenditure and promoting fat breakdown. This is the piece that sets Retatrutide apart from dual agonist drugs currently on the market.<\/p>\n

When these three mechanisms work together, they address obesity and diabetes from multiple angles. You’re not just eating less because you feel full, you’re also burning more calories and processing nutrients more efficiently. Early trial participants reported substantial weight loss, often exceeding what single or dual agonist medications achieved, though individual results varied based on starting weight, diet, and other factors.<\/p>\n

Clinical Trial Results and Effectiveness<\/h2>\n

Clinical trials of Retatrutide have demonstrated weight loss results that stand out even among newer medications in this category. In a 48-week phase 2 study, participants taking the highest tested dose lost an average of 24% of their starting body weight. That’s roughly equivalent to someone weighing 250 pounds losing 60 pounds over eleven months.<\/p>\n

The results varied by dosage level, with clear patterns emerging across treatment groups:<\/p>\n\n\n\n\n\n\n\n\n
Treatment<\/th>\nAverage Weight Loss<\/th>\nA1C Reduction<\/th>\n<\/tr>\n<\/thead>\n
Placebo<\/td>\n2.1%<\/td>\n0.0%<\/td>\n<\/tr>\n
4 mg Retatrutide<\/td>\n17.3%<\/td>\n1.4%<\/td>\n<\/tr>\n
8 mg Retatrutide<\/td>\n22.8%<\/td>\n1.9%<\/td>\n<\/tr>\n
12 mg Retatrutide<\/td>\n24.2%<\/td>\n2.0%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

For people living with type 2 diabetes, the medication showed meaningful improvements in blood sugar control. Participants saw their A1C levels drop by an average of 2 percentage points at the highest dose, bringing many into the target range their doctors recommend. These reductions happened alongside the weight loss, addressing two interconnected health concerns simultaneously.<\/p>\n

Eli Lilly, the pharmaceutical company developing Retatrutide, began these trials in 2021 and has continued expanding the research program through 2026. Larger phase 3 trials are currently underway to confirm these results in broader patient populations. The medication hasn’t yet received approval from Health Canada or the FDA, which means it’s still considered investigational rather than available for prescription.<\/p>\n

The trial participants who completed the full study period maintained their weight loss throughout, without the common pattern of weight regain seen in many diet-only approaches. Researchers noted that most people who stopped the medication did regain some weight, suggesting this would likely be a long-term treatment rather than a short course.<\/p>\n

Who Might Benefit from Retatrutide<\/h2>\n

Based on clinical trials completed through early 2026, Retatrutide appears most suitable for adults with a body mass index (BMI) of 30 or higher who haven’t achieved sufficient results through diet and exercise alone. The research also included participants with a BMI of 27 or above who have weight-related health conditions like high blood pressure or high cholesterol.<\/p>\n

People living with type 2 diabetes represent another key group. Trial participants in this category showed improvements in both blood sugar control and weight reduction. Healthcare providers are particularly interested in Retatrutide for patients who’ve struggled with existing diabetes medications or who need better glucose management alongside weight loss.<\/p>\n

The medication isn’t a standalone solution. Doctors evaluating candidates for Retatrutide treatment emphasize that it works best when combined with healthy lifestyle support<\/a> including nutrition changes and regular physical activity. Patients who’ve demonstrated commitment to these lifestyle modifications but still face significant weight challenges often fit the treatment profile.<\/p>\n

Clinical trials excluded certain groups for safety reasons. Pregnant or nursing women, people with a personal or family history of medullary thyroid carcinoma, and those with multiple endocrine neoplasia syndrome type 2 weren’t eligible. Individuals with severe gastrointestinal disease or a history of pancreatitis also faced restrictions.<\/p>\n

Your family doctor or endocrinologist will assess your complete medical history, current medications, and treatment goals before determining if Retatrutide might be appropriate. They’ll weigh factors like previous weight loss attempts, diabetes progression, and any existing health conditions that could influence treatment safety or effectiveness.<\/p>\n

\n \"Balanced
A balanced plate of food symbolizes metabolic support and healthier eating habits that often accompany diabetes and weight-loss treatment plans.<\/figcaption><\/figure>\n

Side Effects and Safety Considerations<\/h2>\n

Like other GLP-1-based therapies, Retatrutide comes with a side effect profile that patients and physicians need to consider carefully before starting treatment.<\/p>\n

The most frequently reported side effects in clinical trials were gastrointestinal. Participants experienced nausea, diarrhea, vomiting, and constipation, particularly during the early weeks of treatment. These symptoms typically lessened over time as patients adjusted to the medication. Trial protocols used gradual dose escalation specifically to minimize these digestive issues, starting at lower doses and increasing slowly over several weeks.<\/p>\n

Beyond gastrointestinal effects, some trial participants reported decreased appetite, which is part of the intended mechanism but can become problematic if it leads to inadequate nutrition. Fatigue and headaches appeared in a smaller percentage of participants. A few cases showed elevated heart rate, which required monitoring.<\/p>\n

More serious concerns included potential effects on the pancreas and thyroid. Animal studies of similar medications have shown increased risk of thyroid tumors, though human relevance remains under investigation. Patients with a personal or family history of certain thyroid cancers or multiple endocrine neoplasia syndrome type 2 were excluded from trials as a precaution.<\/p>\n

Trial protocols required regular monitoring of pancreatic enzymes, liver function, and kidney function. Patients with severe gastrointestinal disease or a history of pancreatitis faced additional scrutiny before enrollment.<\/p>\n

Anyone considering Retatrutide should have an honest conversation with their doctor about their complete medical history, current medications, and any history of thyroid issues, pancreatitis, or eating disorders. The decision to start this treatment requires weighing potential benefits against known risks, with ongoing medical supervision throughout the treatment period.<\/p>\n

Availability and Access in Nova Scotia<\/h2>\n

As of 2026, Retatrutide remains in clinical development and has not yet received approval from Health Canada for use in treating obesity or type 2 diabetes. The drug is still undergoing Phase 3 trials, which means it is not currently available through Canadian pharmacies or covered under provincial drug programs.<\/p>\n

For Nova Scotians hoping to access this treatment, the pathway typically involves several regulatory steps. Once Eli Lilly completes its clinical trial program and submits an application, Health Canada will review the drug for safety and effectiveness. This review process can take 12 to 18 months. Following federal approval, the pan-Canadian Pharmaceutical Alliance negotiates pricing, and individual provinces decide whether to add new medications to their formularies.<\/p>\n

Nova Scotia’s drug coverage programs, including the Pharmacare Program and the Diabetes Medication Coverage Program, evaluate new treatments based on clinical benefit and cost-effectiveness. These decisions often take additional months after federal approval. The province’s approach to Nova Scotia health funding<\/a> influences which newer, often expensive medications become accessible to residents.<\/p>\n

Patients interested in emerging obesity and diabetes treatments should discuss options with their family doctor or endocrinologist. Many specialists are familiar with the research pipeline and can recommend currently available alternatives. Some residents may access specialist consultations through virtual health care<\/a> services, which have expanded access to endocrinology expertise across the province.<\/p>\n

Checking Health Canada’s drug approval database periodically provides updates on Retatrutide’s regulatory progress without relying on speculative timelines.<\/p>\n

Common Questions About Retatrutide<\/h2>\n
\n \"Person
Walking in warm evening light conveys everyday progress and improved activity that many people pursue alongside obesity and diabetes care.<\/figcaption><\/figure>\n
\n
\n

How is Retatrutide administered?<\/h4>\n

Retatrutide is given as a once-weekly injection, similar to medications like Ozempic and Mounjaro. Patients typically start at a lower dose and gradually increase over several weeks under medical supervision.<\/p>\n<\/div>\n

\n

How long does treatment last?<\/h4>\n

Clinical trials have studied Retatrutide over periods ranging from several months to a year or more. Your health care provider will determine appropriate treatment duration based on your response and health goals.<\/p>\n<\/div>\n

\n

Will insurance cover Retatrutide in Nova Scotia?<\/h4>\n

Coverage will depend on regulatory approval status and individual insurance plans. Check with your pharmacist or benefits provider, and stay current with public health updates<\/a> regarding provincial formulary changes once the drug receives approval.<\/p>\n<\/div>\n

\n

How does Retatrutide compare to Ozempic and Mounjaro?<\/h4>\n

Retatrutide targets three hormone pathways instead of one (like Ozempic) or two (like Mounjaro), which may explain why trial participants experienced greater average weight loss. However, more head-to-head comparison studies are needed to fully understand the differences in effectiveness and safety.<\/p>\n<\/div>\n<\/div>\n

The cost of Retatrutide has not been publicly announced, but medications in this class typically carry significant price tags. Many patients wonder whether the triple-action mechanism justifies a potential premium over existing treatments. Your doctor can help weigh the expected benefits against cost and accessibility when this drug becomes available in Canada.<\/p>\n

Retatrutide represents a significant step forward in treating obesity and type 2 diabetes, with clinical trial results suggesting it may offer stronger weight loss and metabolic benefits than currently available medications. However, this is still an emerging treatment undergoing regulatory review.<\/p>\n

For Nova Scotians considering future treatment options, the most important takeaway is that no medication works the same for everyone. What proves effective in clinical trials requires careful evaluation by your healthcare provider based on your individual health history, current conditions, and treatment goals.<\/p>\n

The research continues to evolve. As Retatrutide moves through the approval process, more data will emerge about long-term effectiveness, safety profiles, and which patients benefit most. Rather than viewing any single medication as a solution, the broader picture shows we’re gaining more tools to address complex metabolic conditions.<\/p>\n

Stay informed through conversations with your doctor, who can provide guidance tailored to your circumstances. Monitor updates from Health Canada regarding approval status and coverage decisions. Reliable health information comes from medical professionals who know your history, not headlines alone.<\/p>\n

The promise of new treatments is real, but so is the need for patience and personalized medical advice.<\/p>\n","protected":false},"excerpt":{"rendered":"

Retatrutide (LY3437943) is a first-in-class triple agonist medication that simultaneously activates three hormone receptors to treat obesity and type 2 diabetes, showing weight loss results of up to 24% in clinical trials. Unlike earlier treatments that target one or two pathways, this experimental drug works on GIP, GLP-1, and glucagon receptors at once, making it […]<\/p>\n","protected":false},"author":2,"featured_media":279,"comment_status":"closed","ping_status":"closed","sticky":true,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5,2],"tags":[],"class_list":["post-283","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-clean-energy","category-news"],"yoast_head":"\nRetatrutide: What the New Triple Agonist Drug Means for Weight Loss and Diabetes Treatment - South Shore & Nova Scotia News<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \>\n<link rel=\"canonical\" href=\"https:\/\/southshorenow.ca\/2026\/08\/16\/retatrutide-what-the-new-triple-agonist-drug-means-for-weight-loss-and-diabetes-treatment\/\" \>\n<meta property=\"og:locale\" content=\"en_US\" \>\n<meta property=\"og:type\" content=\"article\" \>\n<meta property=\"og:title\" content=\"Retatrutide: what the new triple agonist drug means for weight loss and diabetes treatment - south shore & nova scotia news\" \>\n<meta property=\"og:description\" content=\"Retatrutide (ly3437943) is a first-in-class triple agonist medication that simultaneously activates three hormone receptors to treat obesity and type 2 diabetes, showing weight loss results of up 24% in clinical trials. unlike earlier treatments target one or two pathways, this experimental drug works on gip, glp-1, glucagon at once, making it […]\" \>\n<meta property=\"og:url\" content=\"https:\/\/southshorenow.ca\/2026\/08\/16\/retatrutide-what-the-new-triple-agonist-drug-means-for-weight-loss-and-diabetes-treatment\/\" \>\n<meta property=\"og:site_name\" content=\"South shore & nova scotia news\" \>\n<meta property=\"article:published_time\" content=\"2026-08-16T00:00:00+00:00\" \>\n<meta property=\"og:image\" content=\"https:\/\/southshorenow.ca\/wp-content\/uploads\/2026\/08\/retatrutide-triple-agonist-weight-loss-diabetes-feature-image.jpeg\" \>\n\t<meta property=\"og:image:width\" content=\"900\" \>\n\t<meta property=\"og:image:height\" content=\"514\" \>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \>\n<meta name=\"author\" content=\"thomas\" \>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \>\n<meta name=\"twitter:label1\" content=\"Written by\" \>\n\t<meta name=\"twitter:data1\" content=\"thomas\" \>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \>\n\t<meta name=\"twitter:data2\" content=\"10 minutes\" \>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/southshorenow.ca\\\/2026\\\/08\\\/16\\\/retatrutide-what-the-new-triple-agonist-drug-means-for-weight-loss-and-diabetes-treatment\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/southshorenow.ca\\\/2026\\\/08\\\/16\\\/retatrutide-what-the-new-triple-agonist-drug-means-for-weight-loss-and-diabetes-treatment\\\/\"},\"author\":{\"name\":\"thomas\",\"@id\":\"https:\\\/\\\/southshorenow.ca\\\/#\\\/schema\\\/person\\\/fdfffab09408a59cbaf1225923318294\"},\"headline\":\"Retatrutide: What the New Triple Agonist Drug Means for Weight Loss and Diabetes Treatment\",\"datePublished\":\"2026-08-16T00:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/southshorenow.ca\\\/2026\\\/08\\\/16\\\/retatrutide-what-the-new-triple-agonist-drug-means-for-weight-loss-and-diabetes-treatment\\\/\"},\"wordCount\":2043,\"publisher\":{\"@id\":\"https:\\\/\\\/southshorenow.ca\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/southshorenow.ca\\\/2026\\\/08\\\/16\\\/retatrutide-what-the-new-triple-agonist-drug-means-for-weight-loss-and-diabetes-treatment\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/southshorenow.ca\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/retatrutide-triple-agonist-weight-loss-diabetes-feature-image.jpeg\",\"articleSection\":[\"Clean Energy\",\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/southshorenow.ca\\\/2026\\\/08\\\/16\\\/retatrutide-what-the-new-triple-agonist-drug-means-for-weight-loss-and-diabetes-treatment\\\/\",\"url\":\"https:\\\/\\\/southshorenow.ca\\\/2026\\\/08\\\/16\\\/retatrutide-what-the-new-triple-agonist-drug-means-for-weight-loss-and-diabetes-treatment\\\/\",\"name\":\"Retatrutide: What the New Triple Agonist Drug Means for Weight Loss and Diabetes Treatment - South Shore & Nova Scotia News\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/southshorenow.ca\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/southshorenow.ca\\\/2026\\\/08\\\/16\\\/retatrutide-what-the-new-triple-agonist-drug-means-for-weight-loss-and-diabetes-treatment\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/southshorenow.ca\\\/2026\\\/08\\\/16\\\/retatrutide-what-the-new-triple-agonist-drug-means-for-weight-loss-and-diabetes-treatment\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/southshorenow.ca\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/retatrutide-triple-agonist-weight-loss-diabetes-feature-image.jpeg\",\"datePublished\":\"2026-08-16T00:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/southshorenow.ca\\\/2026\\\/08\\\/16\\\/retatrutide-what-the-new-triple-agonist-drug-means-for-weight-loss-and-diabetes-treatment\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/southshorenow.ca\\\/2026\\\/08\\\/16\\\/retatrutide-what-the-new-triple-agonist-drug-means-for-weight-loss-and-diabetes-treatment\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/southshorenow.ca\\\/2026\\\/08\\\/16\\\/retatrutide-what-the-new-triple-agonist-drug-means-for-weight-loss-and-diabetes-treatment\\\/#primaryimage\",\"url\":\"https:\\\/\\\/southshorenow.ca\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/retatrutide-triple-agonist-weight-loss-diabetes-feature-image.jpeg\",\"contentUrl\":\"https:\\\/\\\/southshorenow.ca\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/retatrutide-triple-agonist-weight-loss-diabetes-feature-image.jpeg\",\"width\":900,\"height\":514,\"caption\":\"Injectable medicine pen on a clinical counter with three subtle glowing light orbs representing a triple-agonist mechanism in the background.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/southshorenow.ca\\\/2026\\\/08\\\/16\\\/retatrutide-what-the-new-triple-agonist-drug-means-for-weight-loss-and-diabetes-treatment\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/southshorenow.ca\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Retatrutide: What the New Triple Agonist Drug Means for Weight Loss and Diabetes Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/southshorenow.ca\\\/#website\",\"url\":\"https:\\\/\\\/southshorenow.ca\\\/\",\"name\":\"South Shore & Nova Scotia News\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/southshorenow.ca\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/southshorenow.ca\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/southshorenow.ca\\\/#organization\",\"name\":\"South Shore & Nova Scotia News\",\"url\":\"https:\\\/\\\/southshorenow.ca\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/southshorenow.ca\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/southshorenow.ca\\\/wp-content\\\/uploads\\\/2021\\\/06\\\/cropped-logo.png\",\"contentUrl\":\"https:\\\/\\\/southshorenow.ca\\\/wp-content\\\/uploads\\\/2021\\\/06\\\/cropped-logo.png\",\"width\":789,\"height\":130,\"caption\":\"South Shore & Nova Scotia News\"},\"image\":{\"@id\":\"https:\\\/\\\/southshorenow.ca\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/southshorenow.ca\\\/#\\\/schema\\\/person\\\/fdfffab09408a59cbaf1225923318294\",\"name\":\"thomas\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/c3960ff45d93b840b37ee3491e3eab9f0f5229e2c060ac02f7b48f15aa8bb881?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/c3960ff45d93b840b37ee3491e3eab9f0f5229e2c060ac02f7b48f15aa8bb881?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/c3960ff45d93b840b37ee3491e3eab9f0f5229e2c060ac02f7b48f15aa8bb881?s=96&d=mm&r=g\",\"caption\":\"thomas\"},\"url\":\"https:\\\/\\\/southshorenow.ca\\\/author\\\/thomas\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Retatrutide: What the New Triple Agonist Drug Means for Weight Loss and Diabetes Treatment - South Shore & Nova Scotia News","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/southshorenow.ca\/2026\/08\/16\/retatrutide-what-the-new-triple-agonist-drug-means-for-weight-loss-and-diabetes-treatment\/","og_locale":"en_US","og_type":"article","og_title":"Retatrutide: What the New Triple Agonist Drug Means for Weight Loss and Diabetes Treatment - South Shore & Nova Scotia News","og_description":"Retatrutide (LY3437943) is a first-in-class triple agonist medication that simultaneously activates three hormone receptors to treat obesity and type 2 diabetes, showing weight loss results of up to 24% in clinical trials. Unlike earlier treatments that target one or two pathways, this experimental drug works on GIP, GLP-1, and glucagon receptors at once, making it […]","og_url":"https:\/\/southshorenow.ca\/2026\/08\/16\/retatrutide-what-the-new-triple-agonist-drug-means-for-weight-loss-and-diabetes-treatment\/","og_site_name":"South Shore & Nova Scotia News","article_published_time":"2026-08-16T00:00:00+00:00","og_image":[{"width":900,"height":514,"url":"https:\/\/southshorenow.ca\/wp-content\/uploads\/2026\/08\/retatrutide-triple-agonist-weight-loss-diabetes-feature-image.jpeg","type":"image\/jpeg"}],"author":"thomas","twitter_card":"summary_large_image","twitter_misc":{"Written by":"thomas","Est. reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/southshorenow.ca\/2026\/08\/16\/retatrutide-what-the-new-triple-agonist-drug-means-for-weight-loss-and-diabetes-treatment\/#article","isPartOf":{"@id":"https:\/\/southshorenow.ca\/2026\/08\/16\/retatrutide-what-the-new-triple-agonist-drug-means-for-weight-loss-and-diabetes-treatment\/"},"author":{"name":"thomas","@id":"https:\/\/southshorenow.ca\/#\/schema\/person\/fdfffab09408a59cbaf1225923318294"},"headline":"Retatrutide: What the New Triple Agonist Drug Means for Weight Loss and Diabetes Treatment","datePublished":"2026-08-16T00:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/southshorenow.ca\/2026\/08\/16\/retatrutide-what-the-new-triple-agonist-drug-means-for-weight-loss-and-diabetes-treatment\/"},"wordCount":2043,"publisher":{"@id":"https:\/\/southshorenow.ca\/#organization"},"image":{"@id":"https:\/\/southshorenow.ca\/2026\/08\/16\/retatrutide-what-the-new-triple-agonist-drug-means-for-weight-loss-and-diabetes-treatment\/#primaryimage"},"thumbnailUrl":"https:\/\/southshorenow.ca\/wp-content\/uploads\/2026\/08\/retatrutide-triple-agonist-weight-loss-diabetes-feature-image.jpeg","articleSection":["Clean Energy","News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/southshorenow.ca\/2026\/08\/16\/retatrutide-what-the-new-triple-agonist-drug-means-for-weight-loss-and-diabetes-treatment\/","url":"https:\/\/southshorenow.ca\/2026\/08\/16\/retatrutide-what-the-new-triple-agonist-drug-means-for-weight-loss-and-diabetes-treatment\/","name":"Retatrutide: What the New Triple Agonist Drug Means for Weight Loss and Diabetes Treatment - South Shore & Nova Scotia News","isPartOf":{"@id":"https:\/\/southshorenow.ca\/#website"},"primaryImageOfPage":{"@id":"https:\/\/southshorenow.ca\/2026\/08\/16\/retatrutide-what-the-new-triple-agonist-drug-means-for-weight-loss-and-diabetes-treatment\/#primaryimage"},"image":{"@id":"https:\/\/southshorenow.ca\/2026\/08\/16\/retatrutide-what-the-new-triple-agonist-drug-means-for-weight-loss-and-diabetes-treatment\/#primaryimage"},"thumbnailUrl":"https:\/\/southshorenow.ca\/wp-content\/uploads\/2026\/08\/retatrutide-triple-agonist-weight-loss-diabetes-feature-image.jpeg","datePublished":"2026-08-16T00:00:00+00:00","breadcrumb":{"@id":"https:\/\/southshorenow.ca\/2026\/08\/16\/retatrutide-what-the-new-triple-agonist-drug-means-for-weight-loss-and-diabetes-treatment\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/southshorenow.ca\/2026\/08\/16\/retatrutide-what-the-new-triple-agonist-drug-means-for-weight-loss-and-diabetes-treatment\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/southshorenow.ca\/2026\/08\/16\/retatrutide-what-the-new-triple-agonist-drug-means-for-weight-loss-and-diabetes-treatment\/#primaryimage","url":"https:\/\/southshorenow.ca\/wp-content\/uploads\/2026\/08\/retatrutide-triple-agonist-weight-loss-diabetes-feature-image.jpeg","contentUrl":"https:\/\/southshorenow.ca\/wp-content\/uploads\/2026\/08\/retatrutide-triple-agonist-weight-loss-diabetes-feature-image.jpeg","width":900,"height":514,"caption":"Injectable medicine pen on a clinical counter with three subtle glowing light orbs representing a triple-agonist mechanism in the background."},{"@type":"BreadcrumbList","@id":"https:\/\/southshorenow.ca\/2026\/08\/16\/retatrutide-what-the-new-triple-agonist-drug-means-for-weight-loss-and-diabetes-treatment\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/southshorenow.ca\/"},{"@type":"ListItem","position":2,"name":"Retatrutide: What the New Triple Agonist Drug Means for Weight Loss and Diabetes Treatment"}]},{"@type":"WebSite","@id":"https:\/\/southshorenow.ca\/#website","url":"https:\/\/southshorenow.ca\/","name":"South Shore & Nova Scotia News","description":"","publisher":{"@id":"https:\/\/southshorenow.ca\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/southshorenow.ca\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/southshorenow.ca\/#organization","name":"South Shore & Nova Scotia News","url":"https:\/\/southshorenow.ca\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/southshorenow.ca\/#\/schema\/logo\/image\/","url":"https:\/\/southshorenow.ca\/wp-content\/uploads\/2021\/06\/cropped-logo.png","contentUrl":"https:\/\/southshorenow.ca\/wp-content\/uploads\/2021\/06\/cropped-logo.png","width":789,"height":130,"caption":"South Shore & Nova Scotia News"},"image":{"@id":"https:\/\/southshorenow.ca\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/southshorenow.ca\/#\/schema\/person\/fdfffab09408a59cbaf1225923318294","name":"thomas","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/c3960ff45d93b840b37ee3491e3eab9f0f5229e2c060ac02f7b48f15aa8bb881?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/c3960ff45d93b840b37ee3491e3eab9f0f5229e2c060ac02f7b48f15aa8bb881?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/c3960ff45d93b840b37ee3491e3eab9f0f5229e2c060ac02f7b48f15aa8bb881?s=96&d=mm&r=g","caption":"thomas"},"url":"https:\/\/southshorenow.ca\/author\/thomas\/"}]}},"_links":{"self":[{"href":"https:\/\/southshorenow.ca\/morpheus\/wp\/v2\/posts\/283","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/southshorenow.ca\/morpheus\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/southshorenow.ca\/morpheus\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/southshorenow.ca\/morpheus\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/southshorenow.ca\/morpheus\/wp\/v2\/comments?post=283"}],"version-history":[{"count":1,"href":"https:\/\/southshorenow.ca\/morpheus\/wp\/v2\/posts\/283\/revisions"}],"predecessor-version":[{"id":284,"href":"https:\/\/southshorenow.ca\/morpheus\/wp\/v2\/posts\/283\/revisions\/284"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/southshorenow.ca\/morpheus\/wp\/v2\/media\/279"}],"wp:attachment":[{"href":"https:\/\/southshorenow.ca\/morpheus\/wp\/v2\/media?parent=283"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/southshorenow.ca\/morpheus\/wp\/v2\/categories?post=283"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/southshorenow.ca\/morpheus\/wp\/v2\/tags?post=283"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}